Literature DB >> 28092287

Current and future management of the young child with early onset wheezing.

Allison J Burbank1, Stanley J Szefler.   

Abstract

PURPOSE OF REVIEW: In this review, we discuss current thinking in relation to available guidelines for the care of preschool-aged children with recurrent wheezing, while highlighting the gaps in our knowledge and discussing changes that could occur over the next 5 years. RECENT
FINDINGS: The Asthma Predictive Index as well as allergen-specific IgE, peripheral eosinophil count and exhaled nitric oxide are perhaps underutilized sources of information that can assist in predicting progression to asthma and response to therapies. Inhaled corticosteroids and leukotriene receptor antagonists decrease impairment and exacerbation frequency in wheezing children but are not disease modifying. Macrolides may be useful during acute wheezing episodes for preventing progression to more severe symptoms. Monoclonal antibodies targeting IgE and TH2 cytokines have been successful in trials of adults and older children with asthma, but trials in younger children are needed.
SUMMARY: Establishing the phenotype and endotype of young wheezing children can be useful for prognostication of future asthma risk as well as for selection of the most appropriate treatment. Primary asthma prevention strategies are needed during the critical developmental window in early life prior to the onset of irrecoverable loss of lung function.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28092287      PMCID: PMC5550831          DOI: 10.1097/ACI.0000000000000341

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  71 in total

1.  A clinical index to define risk of asthma in young children with recurrent wheezing.

Authors:  J A Castro-Rodríguez; C J Holberg; A L Wright; F D Martinez
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Wheezing requiring hospitalization in early childhood: predictive factors for asthma in a six-year follow-up.

Authors:  Anne Kotaniemi-Syrjänen; Tiina M Reijonen; Kaj Korhonen; Matti Korppi
Journal:  Pediatr Allergy Immunol       Date:  2002-12       Impact factor: 6.377

3.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

4.  Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE.

Authors:  Daan Caudri; Alet H Wijga; Maarten O Hoekstra; Marjan Kerkhof; Gerard H Koppelman; Bert Brunekreef; Henriette A Smit; Johan C de Jongste
Journal:  Thorax       Date:  2010-09       Impact factor: 9.139

5.  Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.

Authors:  Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig
Journal:  J Allergy Clin Immunol       Date:  2005-02       Impact factor: 10.793

6.  Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma.

Authors:  Nandini Krishnamoorthy; Anupriya Khare; Timothy B Oriss; Mahesh Raundhal; Christina Morse; Manohar Yarlagadda; Sally E Wenzel; Martin L Moore; R Stokes Peebles; Anuradha Ray; Prabir Ray
Journal:  Nat Med       Date:  2012-09-09       Impact factor: 53.440

Review 7.  Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report.

Authors:  L B Bacharier; A Boner; K-H Carlsen; P A Eigenmann; T Frischer; M Götz; P J Helms; J Hunt; A Liu; N Papadopoulos; T Platts-Mills; P Pohunek; F E R Simons; E Valovirta; U Wahn; J Wildhaber
Journal:  Allergy       Date:  2008-01       Impact factor: 13.146

8.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

9.  Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts.

Authors:  N Lazic; G Roberts; A Custovic; D Belgrave; C M Bishop; J Winn; J A Curtin; S Hasan Arshad; A Simpson
Journal:  Allergy       Date:  2013-04-29       Impact factor: 13.146

10.  Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial.

Authors:  Jakob Stokholm; Bo L Chawes; Nadja H Vissing; Elín Bjarnadóttir; Tine M Pedersen; Rebecca K Vinding; Ann-Marie M Schoos; Helene M Wolsk; Sunna Thorsteinsdóttir; Henrik W Hallas; Lambang Arianto; Susanne Schjørring; Karen A Krogfelt; Thea K Fischer; Christian B Pipper; Klaus Bønnelykke; Hans Bisgaard
Journal:  Lancet Respir Med       Date:  2015-12-17       Impact factor: 30.700

View more
  2 in total

1.  Things We Do for No Reason: Systemic Corticosteroids for Wheezing in Preschool-Aged Children.

Authors:  Yemisi O Jones; Brittany B Hubbell; Joanna Thomson; Jennifer K O'Toole
Journal:  J Hosp Med       Date:  2019-07-24       Impact factor: 2.960

2.  Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years.

Authors:  Orianne Dumas; Kohei Hasegawa; Jonathan M Mansbach; Ashley F Sullivan; Pedro A Piedra; Carlos A Camargo
Journal:  J Allergy Clin Immunol       Date:  2018-09-18       Impact factor: 10.793

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.